Circulating soluble LIGHT/TNFSF14 is increased and associated with IL-8 concentration in chronic spontaneous urticaria

Alicja Kasperska-Zając¹,², Aleksandra Damasiewicz-Bodzek², Ryszard Grzanka¹, Agnieszka Skrzypulec-Frankel¹,², Katarzyna Bieniek¹,², Agnieszka Sikora-Żydek¹,² and Jerzy Jochem⁴

Abstract
LIGHT (homologous to lymphotoxins, exhibiting inducible expression, and competing with herpes simplex virus (HSV) glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) has been involved in various autoimmune and inflammatory disorders. LIGHT induces the expression of interleukin-8 (IL-8), which is up-regulated in chronic spontaneous urticaria (CSU). To determine circulating soluble LIGHT concentration and its relationship with IL-8 concentration in patients with CSU. Concentrations of LIGHT, IL-8, and C-reactive protein (CRP) were determined in plasma or serum of CSU patients by an enzyme-linked immunosorbent assay. LIGHT plasma concentration was significantly higher in moderate–severe CSU patients as compared with the healthy subjects, but not with mild CSU patients. There were significant correlations between increased LIGHT and IL-8 concentrations, but not with increased CRP in CSU patients. Enhanced plasma concentrations of soluble LIGHT and its association with IL-8 concentration suggest the role of LIGHT in systemic inflammatory activation in CSU patients. We hypothesize that LIGHT-mediated immune–inflammatory response plays a role in severe phenotypes of the disease.

Keywords
chronic spontaneous urticaria, IL-8, LIGHT/TNFSF14

Date received: 28 December 2017; accepted: 30 May 2018

Introduction
Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease associated with autoimmune phenomena and systemic inflammatory response.¹,² The tumor necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT (homologous to lymphotoxins, exhibiting inducible expression,

¹Department of Internal Diseases, Dermatology and Allergology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland
²European Center for Diagnosis and Treatment of Urticaria (GA2LEN UCARE Network), Zabrze, Poland
³Department of Chemistry, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland
⁴Department of Physiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland

Corresponding author:
Alicja Kasperska-Zając, Department of Internal Diseases, Dermatology and Allergology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, M. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland. Email: alakasperska@gmail.com
and competing with herpes simplex virus (HSV) glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) has been involved in various autoimmune and inflammatory disorders. LIGHT is known to regulate T cell immune responses and has pro-inflammatory activity. Circulating soluble LIGHT has been reported as a potential biomarker of autoimmune and inflammatory diseases, including atopic dermatitis and scleroderma, but its association with the pathogenesis of CSU has not been clarified. In addition, it has been demonstrated that LIGHT induces the expression of various cytokines that are involved in urticarial inflammation, including interleukin-8 (IL-8), which is up-regulated in CSU patients. Therefore, in this study, we determined plasma LIGHT concentration and its associations with circulating IL-8 and acute phase response in CSU patients.

**Materials and methods**

In total, 52 active CSU patients (14 men and 38 women; median age: 38 years, range: 24–50) and 21 sex-, age-, and body mass index (BMI; <30)-matched healthy subjects were enrolled in the study. Each patient underwent tests, including the autologous serum skin test (ASST) and consultations, which were described previously. The study comprised 28 mild CSU patients and 24 moderate–severe CSU patients graded during 4 days as follows: mild—0 to 8 urticaria activity score (UAS), moderate—9 to 16 UAS, and severe—17 to 24 UAS. H1 antihistamines and immunosuppressants were withdrawn at least 4 days and 8 weeks, respectively, before blood sampling.

The Ethics Committee of the Medical University of Silesia approved the study, and all subjects gave informed, signed consent to participate in the study.

**Blood collection**

Fasting blood samples were collected in a tube with anticoagulants. Plasma samples were frozen at −85°C until the tests were performed.

**Assay of C-reactive protein (CRP)**

Serum CRP concentrations were measured automatically using a Roche/Hitachi cobas c system. Normal lab ranges (<5.0 mg/L).

**Assay of IL-8**

Plasma IL-8 concentrations were measured using a Quantikine Human CXCL8/IL-8 ELISA kit (R&D Systems, MN, USA). The coefficients of variation for intra- and inter-assays were below 8% and 10%, respectively.

**Assay of LIGHT/TNFSF14**

Concentrations of LIGHT in plasma were measured by enzyme-linked immunosorbent assay (ELISA) method using a commercially available kit (Quantikine Human LIGHT/TNFSF14 ELISA kit; R&D Systems, MN, USA). The coefficients of variation for intra- and inter-assays were below 6% and 8%, respectively.

**Statistical analysis**

The results were presented as the median and mean values, quartile range, and standard deviation. Normal data distribution was measured using the Shapiro–Wilk test. The data of the CSU patients and the controls as well as those of the mild and moderate–severe CSU groups were compared using Mann–Whitney U test. Spearman’s rank correlation test was used for correlations. The P value < 0.05 was considered statistically significant. Analyses were performed with Statistica (StatSoft, Cracow, Poland).

**Results**

**Plasma LIGHT concentrations**

No significant differences were observed in LIGHT concentration between the controls and CSU patients (median: 54.77 and 78.07 pg/mL, P > 0.05; Figure 1). LIGHT concentration was significantly higher in moderate–severe CSU patients as compared with the controls, but not with mild disease activity (median: 106.63 vs 54.77 vs 50.94 pg/mL, P > 0.05 and P < 0.05, respectively; Figure 1).

There were no significant differences in LIGHT concentrations between CSU patients with positive and negative ASST responses, selected according to the similar UAS (median: 57.55 vs 97.92 pg/mL, P > 0.05).

**Plasma IL-8 concentrations**

Concentrations of IL-8 were significantly higher in the CSU group versus the controls (median: 8.58 vs 2.5 pg/mL; P < 0.001; Figure 2).
IL-8 concentrations were significantly higher in moderate–severe and mild CSU groups than in the controls (median: 11.61 vs 6.06 vs 2.5 pg/mL, \( P < 0.01 \) and \( P < 0.001 \), respectively). The cytokine concentrations in patients with mild CSU were significantly higher than those in the controls (6.06 vs 2.5 pg/mL, \( P < 0.05 \); Figure 2).

We did not observe any significant difference in IL-8 concentrations between CSU patients with positive and negative ASST responses, selected according to the similar UAS (median: 8.33 vs 8.58 pg/mL, \( P > 0.05 \)).

**Serum CRP concentrations**

CRP concentrations were significantly higher in CSU patients than in the controls (median: 3.8 vs 0.4 mg/L; \( P < 0.001 \)).\(^9\) Significant differences in CRP concentrations between patients with mild and moderate–severe CSU activity and the controls were observed (median: 1.4 vs 9.8 vs 0.4 mg/L, respectively; \( P < 0.001 \)), (the data have been published previously).\(^9\)

There were no significant differences in LIGHT concentrations between CSU patients with positive and negative ASST responses, selected according to the similar UAS (median: 3.9 vs 3.3 mg/L, \( P > 0.05 \)).

**Correlations**

LIGHT concentrations were significantly correlated with IL-8, but not with CRP in CSU (\( R = 0.62, P = 0.000001 \) and \( R = 0.22, P = 0.12 \)). LIGHT concentrations were significantly correlated with IL-8 in CSU ASST− and CSU ASST+ patients (\( R = 0.66, P = 0.00003 \) and \( R = 0.61, P = 0.008 \)).

In addition, there were significant correlations between LIGHT and IL-8, but not with CRP in moderate–severe CSU (\( R = 0.53, P = 0.008 \) and \( R = 0.14, P = 0.52 \)).

There was a significant correlation between IL-8 and CRP (\( R = 0.41, P = 0.002 \)).

There were not any significant correlations between LIGHT and UAS4 (\( R = 0.17, P = 0.23 \), but were present between UAS4 and IL-8 and CRP, as described previously.\(^9\)

The platelet or leukocyte count was not significantly correlated with plasma concentrations of LIGHT in both groups.
Discussion

In our study, plasma concentrations of soluble LIGHT were significantly higher in moderate–severe CSU patients as compared with the controls, but not in patients with mild CSU. It is known that moderate–severe CSU is a difficult-to-treat disease and is associated with increased systemic inflammatory response and autoimmune phenomena. The dysregulation or overexpression of LIGHT plays an important role in the induction and/or persistence of inflammatory response and autoimmunity.3,4 Taken together, it seems that elevated soluble LIGHT concentrations may reflect a persistent chronic inflammatory response that is induced during the moderate–severe activity of CSU.

Previously, we demonstrated that plasma IL-8 concentration is significantly increased in patients with CSU,8 which is in line with the current results. In this study, we observed a significant correlation between LIGHT and IL-8 concentrations in CSU patients, including the ASST– and ASST+ CSU subgroups. There were not significant correlations between LIGHT and UAS4, but between UAS4 and IL-8 and CRP, as described previously.9

Interestingly, it has been demonstrated that LIGHT may induce the expression, production, and release of IL-8.5,10 These results suggest that the triggering of LIGHT in more severe CSU leads to the release of pro-inflammatory mediators, including IL-8. In addition, it has been reported that LIGHT induces the expression of matrix metalloproteinase-9 and pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6).11 Taken together, it seems that LIGHT in CSU may contribute to systemic inflammation, especially in CSU patients with more severe disease activity/severity.

LIGHT as a costimulator plays an important role in the activation/proliferation of T cells3,4 and mast cells in the course of T-cell- or B-cell-dependent inflammatory reactions.12 Dysregulation of LIGHT activity may trigger the abnormal T cell activation, leading to a pathological immune–inflammatory response and autoimmune manifestations.4 LIGHT involvement in inflammatory disorders has also been demonstrated in chronic kidney disease and alkaptonuria.13,14

We speculate that the immune response switches to processes involving LIGHT in severe phenotypes.
of CSU. The underlying mechanism by which LIGHT mediates urticarial processes and its sources in CSU remains unknown. LIGHT (TNFSF14) is a transmembrane protein expressed and shed from different types of immune–inflammatory cells, including T and B lymphocytes, monocytes/macrophages, granulocytes, spleen cells, and dendritic cells,\textsuperscript{3–5} which may be involved in CSU. CRP concentrations were significantly higher in CSU patients than in the controls, thus confirming previous observations.\textsuperscript{15}

In conclusion, enhanced plasma concentrations of soluble LIGHT and its association with IL-8 concentration suggest the role of LIGHT in systemic inflammatory activation in CSU patients.

We hypothesize that LIGHT-mediated immune–inflammatory response plays a role in severe phenotypes of the disease.

Acknowledgements

A.K.-Z. designed the study as well as reviewed the manuscript. A.D.-B. performed the lab and statistical data analysis and wrote the manuscript. R.G., A.S.-Z., A.S.-F., and K.B. collected the samples and provided clinical data. All authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This study was supported by the Committee for Scientific Research (KNW-1-041/K/6/K); it does not lead to any conflicts of interest regarding the publication of this manuscript.

ORCID iD

Alicja Kasperska-Zając https://orcid.org/0000-0002-2000-0070

References

1. Asero R, Tedeschi A, Marzano AV, et al. (2016) Chronic spontaneous urticaria: Immune system, blood coagulation, and more. Expert Review of Clinical Immunology 12: 229–231.
2. Kasperska-Zając A, Grzanka A and Damasiewicz-Bodzek A (2015) IL-6 signaling in chronic spontaneous urticaria. PLoS ONE 10: e0145751.
3. Wang J and Fu YX (2004) The role of LIGHT in T cell-mediated immunity. Immunologic Research 30: 201–214.
4. Wang J, Lo JC, Foster A, et al. (2001) The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. The Journal of Clinical Investigation 108: 1771–1780.
5. Lim SG, Suk K and Lee WH (2013) Reverse signaling from LIGHT promotes pro-inflammatory responses in the human monocytic leukemia cell line, THP-1. Cellular Immunology 285: 10–17.
6. Herro R, Antunes Rda S, Aguilera AR, et al. (2015) The tumor necrosis factor superfamily molecule LIGHT promotes keratinocyte activity and skin fibrosis. Journal of Investigative Dermatology 135: 2109–2118.
7. Kotani H, Masuda K, Tamagawa-Mineoka R, et al. (2012) Increased plasma LIGHT levels in patients with atopic dermatitis. Clinical and Experimental Immunology 168: 318–324.
8. Kasperska-Zając A, Grzanka A, Damasiewicz-Bodzek A, et al. (2017) Elevated plasma IL-8 concentration is related to severity of systemic inflammation in chronic spontaneous urticaria. Journal of Biological Regulators & Homeostatic Agents 31: 957–961.
9. Grzanka A, Damasiewicz-Bodzek A and Kasperska-Zając A (2017) The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria. Allergy, Asthma, and Clinical Immunology 13: 25.
10. Otterdal K, Haukeland JW, Yndestad A, et al. (2015) Increased serum levels of LIGHT/TNFSF14 in nonalcoholic fatty liver disease: Possible role in hepatic inflammation. Clinical and Translational Gastroenterology 6: e95.
11. Kim WJ, Kang YJ, Koh EM, et al. (2005) LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages. Immunology 114: 272–279.
12. Stopfer P, Männel DN and Hehlgans T (2004) Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. Journal of Immunology 172: 7459–7465.
13. Cafiero C, Gigante M and Brunetti G (2018) Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: Crosstalk between the immune and bone systems. Nephrology, Dialysis, Transplantation 33: 65–75.
14. Brunetti G, Tummolo A, D’Amato G, et al. (2018) Mechanisms of enhanced osteoclastogenesis in alkaptonuria. The American journal of pathology 188: 1059–1068.
15. Kasperska-Zając A, Damasiewicz-Bodzek A, Bieniek K, et al. (2018) Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria. International Journal of Immunopathology and Pharmacology 31: 394632017750440.